TY - JOUR T1 - The effect of Alzheimer’s disease-associated genetic variants on longevity JF - medRxiv DO - 10.1101/2021.02.02.21250991 SP - 2021.02.02.21250991 AU - Niccolò Tesi AU - Marc Hulsman AU - Sven J. van der Lee AU - Iris E. Jansen AU - Najada Stringa AU - Natasja M. van Schoor AU - Philip Scheltens AU - Wiesje M. van der Flier AU - Martijn Huisman AU - Marcel J. T. Reinders AU - Henne Holstege Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/04/2021.02.02.21250991.abstract N2 - The genetics underlying human longevity is influenced by the genetic risk to develop -or escape- age-related diseases. As Alzheimer’s disease (AD) represents one of the most common conditions at old age, an interplay between genetic factors for AD and longevity is expected.We explored this interplay by studying the prevalence of 38 AD-associated single-nucleotide-polymorphisms (SNPs) identified in AD-GWAS, in self-reported cognitively healthy centenarians, and we replicated findings in the largest GWAS on parental-longevity.We found that 28/38 SNPs identified to associate with increased AD-risk also associated with decreased odds of longevity. For each SNP, we express the imbalance between AD- and longevity-risk as an effect-size distribution. When grouping the SNPs based on these distributions, we found three groups: 17 variants increased AD-risk more than they decreased the risk of longevity (AD-group): these variants were functionally enriched for β-amyloid metabolism and immune signaling, and they were enriched in microglia. 11 variants reported a larger effect on longevity as compared to their AD-effect (Longevity-group): these variants were enriched for endocytosis/immune signaling, and at the cell-type level were enriched in microglia and endothelial cells. Next to AD, these variants were previously associated with other aging-related diseases, including cardiovascular and autoimmune diseases, and cancer. Unexpectedly, 10 variants associated with an increased risk of both AD and longevity (Unexpected-group). The effect of the SNPs in AD- and Longevity-groups replicated in the largest GWAS on parental-longevity, while the effects on longevity of the SNPs in the Unexpected-group could not be replicated, suggesting that these effects may not be robust across different studies.Our study shows that some AD-associated variants negatively affect longevity primarily by their increased risk of AD, while other variants negatively affect longevity through an increased risk of multiple age-related diseases, including AD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAcknowledgments: The following studies and consortia have contributed to this manuscript. Amsterdam Dementia Cohort (ADC): Research at the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. 100-plus Study: we are grateful for the collaborative efforts of all participating centenarians and their family members and/or relatives. Wiesje van der Flier holds the Pasman chair. Longitudinal Aging Study of Amsterdam (LASA): the authors are grateful to all LASA participants, the fieldwork team and all researchers for their ongoing commitment to the study. Funding: The Alzheimer center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. The SCIENCe project is supported by a research grant from Gieskes-Strijbis fonds and stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank), funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). The 100-plus Study was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting Diorapthe, horstingstuit foundation, Memorabel (ZonMW projectnumber 733050814), and Stichting VUmc fonds. Genotyping of the 100-plus study was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Ethics Committee of the Amsterdam UMC (METC) approved all studies. All participants and/or their legal representatives provided written informed consent for participation in clinical and genetic studies.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability: data that support the findings of this study are available on request, if reasonable, from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. ER -